Pluri prices $1.50 registered offering, plans concurrent private placement warrants

Pluri Inc., a biotechnology company trading on Nasdaq under the symbol "PLUR," priced a registered direct offering on August 26, 2026, according to a prospectus supplement filed with the SEC. The company is offering 1,200,000 common shares together with pre-funded warrants to purchase up to 1,028,940 additional common shares.¹ Each common share or pre-funded warrant is being sold together with one warrant to purchase one common share, at a combined purchase price of $1.50 per common share and accompanying warrant.¹

In a concurrent private placement with the same investor, Pluri is issuing unregistered warrants to purchase up to 2,228,940 common shares, exercisable six months after issuance and expiring five and a half years from issuance, at an exercise price of $1.65 per share.¹

Delivery of the securities is expected to be made on or about August 28, 2026, subject to the satisfaction of certain closing conditions.¹ The filing does not state that the offering has closed.

Pluri estimated net proceeds from the offering and the concurrent private placement at approximately $2,984,798, after deducting placement agent commissions and estimated offering expenses.¹ The company said it intends to use the net proceeds for corporate development, general purposes and working capital.¹

Separately, Pluri filed a Form D notice of an exempt securities offering tied to the private placement warrants. The total offering amount and total amount sold were both listed as $3,677,751, with the total remaining to be sold shown as $0.² The filing clarifies that this figure reflects total gross proceeds to the company assuming cash exercise of all the warrants, and does not include proceeds from the concurrent registered direct offering.² The Form D is a notice of the exempt offering of those warrants and the shares issuable upon their exercise, not a record confirming that the warrants have been exercised.

As of March 31, 2026, Pluri had cash balances of approximately $10.5 million against total current liabilities of about $32.0 million, a working capital deficit of roughly $21.5 million, and had disclosed substantial doubt about its ability to continue as a going concern.¹